Navigation Links
Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board
Date:11/6/2008

- A Strong International Strategy for Invisicare Is Put In Place

LAS VEGAS, Nov. 6 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI), the developers of Invisicare, a patented polymer delivery system that enhances topically applied products, today announced the appointment of Geert Cauwenbergh, PhD to head its International Advisory Board and to spear-head a focused strategy to expand the demand for Invisicare in international markets. Dr. Cauwenbergh has vast international experience in the dermatology market including research, development and the successful commercialization of pharmaceutical products with Barrier Therapeutics, Johnson and Johnson (NYSE: JNJ) and Janssen Pharmaceutica.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO)

Dr. Cauwenbergh's career has been focused in dermatology. Early in his career he was the International Director of Clinical R&D, Dermatology and Infectious Diseases at the Janssen Research Foundation at Janssen Pharmaceutica in Belgium. This was followed with executive roles at Johnson & Johnson (J&J) including VP Research & Development for J&J Consumer Companies Worldwide, VP Product Development, as well as serving on the J&J Consumer Company's Management Board and Director of J&J' s Corporate Skin Care Council.

In 2001 he founded Barrier Therapeutics with offices in the US and Belgium, raising over $250 million in venture capital as well as a listing on the NASDAQ stock exchange. He developed a port
'/>"/>

SOURCE Skinvisible, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Skinvisible to Present at Merriman Curhan Ford & Co.s Investor Summit 2007
2. Skinvisible Appoints Dr. George Korkos to Its Advisory Board
3. Skinvisible Signs Marketing Agreement for India
4. Skinvisible Announces Licensing Agreement for Adapalene
5. Skinvisible Appoints New Board Member
6. Skinvisible Signs Licensing Agreement for Two Acne Formulations
7. Skinvisible Appoints New Vice President of Business Development & Marketing
8. Skinvisible Offers 8 Hour Photostablity for Parsol 1789
9. WorldHeart Appoints David Pellone Chief Financial Officer
10. Novo Nordisk Appoints New Leader of North American Business
11. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus 2Health News:Americans United for Life Action Fights the Abortion Bailout by Supporting the Nelson-Hatch-Casey Amendment 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug Resistant Influenza Viruses 4981 1In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug Resistant Influenza Viruses 4981 2In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug Resistant Influenza Viruses 4981 3In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug Resistant Influenza Viruses 4981 4Opto electronic nose sniffs out toxic gases 9902 1Opto electronic nose sniffs out toxic gases 9902 2Opto electronic nose sniffs out toxic gases 9902 3Are the monoamines involved in shaping conduct disorders 3F 9898 1Are the monoamines involved in shaping conduct disorders 3F 9898 2Are the monoamines involved in shaping conduct disorders 3F 9898 3Are the monoamines involved in shaping conduct disorders 3F 9898 4Are the monoamines involved in shaping conduct disorders 3F 9898 5Are the monoamines involved in shaping conduct disorders 3F 9898 6